Nuvigil action date extension
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA's revised user fee date for Cephalon's excessive daytime sleepiness agent Nuvigil (armodafinil) is April 30 following a 90-day extension. The agency deemed additional information, submitted in October, to be a major amendment to Cephalon's NDA. The firm maintains that it does not expect further delays and continues to expect a mid-2006 launch. Nuvigil is a follow-on compound to Cephalon's sleepiness agent Provigil (modafinil), which could see generic competition by mid-2006...
You may also be interested in...
Nuvigil Label Likely To Include Safety Information From Sparlon Trials
Final approved labeling for Cephalon’s Nuvigil (armodafinil) will likely include results of an FDA safety review for the firm’s other pending product, attention deficit hyperactivity disorder treatment Sparlon (modafinil).
Cephalon To File Gabitril Generalized Anxiety Disorder Claim By Mid-Year
Cephalon plans to file an sNDA by mid-year for expanded use of its anti-seizure medication Gabitril to treat generalized anxiety disorder, pending the outcome of Phase III trials
Cosmetics Europe Talks Microplastic: ECHA Frustrations, ‘Value Judgments’ And International Trade Uncertainty
The European Chemicals Agency's microplastic restriction proposal received committee backing in 2020 without changes sought by the cosmetics industry, which faces €15bn in projected costs and scarce alternatives at present. It may come down to EU Member States to decide whether the ECHA restriction proposal is proportionate in balancing environmental goals and socio-economic impacts.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: